AZD 2995

Drug Profile

AZD 2995

Alternative Names: [11C]AZD 2995; AZD2995

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis) in Sweden (IV, Injection)
  • 26 Jun 2013 Navidea Biopharmaceuticals secures loan ($US25 million) from GE Capital, Healthcare Financial Services to support development of the company's pipeline and for other purposes
  • 15 Jan 2013 AZD 2995 licensed to Navidea Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top